The study, titled “ Strategic Help with Immunoglobulin to Enhance protection against Late Disease (CMV) ” or SHIELD, is a prospective, randomized, controlled multicenter investigator-initiated study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback